Peter Sallstig

Head, Representative, US R&D,
Corporate Officer

Flavio Lima

Vice President,
Global Medical Affairs

GMA Team Holiday Message

Santen Receives U.S. FDA Approval for Verkazia (Cyclosporine Ophthalmic Emulsion, 0.1%) for the Treatment of Vernal Keratoconjunctivitis in Children and Adults

Santen and Glaukos Enter into a New Collaboration in the Development and Commercialization of STN2000100 (DE-128) in the Americas, Australia, and New Zealand
Research initiative focuses on new glaucoma treatments
FDA approves cyclosporine A drop for vernal keratoconjunctivitis
Omidenepag isopropyl ophthalmic solution for open-angle glaucoma and ocular hypertension: an update
A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Twenty-Four-Hour Intraocular Pressure Control with Omidenepag Isopropyl 0.002% in Patients with Glaucoma and Ocular Hypertension
Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study
*The MicroShunt is CE Marked in Europe and approved in Canada by Health Canada marketed under the brand name PRESERFLO The MicroShunt is pending PMA approval by the FDA and is not available for sale within the United States.
© Santen Incorporated. All rights reserved.
AB-CD-EFG-0000 – Ver 1.0